Literature DB >> 19897346

Tea catechins' affinity for human cannabinoid receptors.

G Korte1, A Dreiseitel, P Schreier, A Oehme, S Locher, S Geiger, J Heilmann, P G Sand.   

Abstract

Among the many known health benefits of tea catechins count anti-inflammatory and neuroprotective activities, as well as effects on the regulation of food intake. Here we address cannabimimetic bioactivity of catechin derivatives occurring in tea leaves as a possible cellular effector of these functionalities. Competitive radioligand binding assays using recombinant human cannabinoid receptors expressed in Chem-1 and CHO cells identified (-)-epigallocatechin-3-O-gallate, EGCG (K(i)=33.6 microM), (-)-epigallocatechin, EGC (K(i)=35.7 microM), and (-)-epicatechin-3-O-gallate, ECG (K(i)=47.3 microM) as ligands with moderate affinity for type 1 cannabinoid receptors, CB1. Binding to CB2 was weaker with inhibition constants exceeding 50 microM for EGC and ECG. The epimers (+)-catechin and (-)-epicatechin exhibited negligible affinities for both CB1 and CB2. It can be concluded that central nervous cannabinoid receptors may be targeted by selected tea catechins but signaling via peripheral type receptors is less likely to play a major role in vivo.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19897346     DOI: 10.1016/j.phymed.2009.10.001

Source DB:  PubMed          Journal:  Phytomedicine        ISSN: 0944-7113            Impact factor:   5.340


  8 in total

Review 1.  Phytocannabinoids beyond the Cannabis plant - do they exist?

Authors:  Jürg Gertsch; Roger G Pertwee; Vincenzo Di Marzo
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

Review 2.  Flavonoids: structure-function and mechanisms of action and opportunities for drug development.

Authors:  Stephen Safe; Arul Jayaraman; Robert S Chapkin; Marcell Howard; Kumaravel Mohankumar; Rupesh Shrestha
Journal:  Toxicol Res       Date:  2021-01-20

Review 3.  DYRK1A, a Dosage-Sensitive Gene Involved in Neurodevelopmental Disorders, Is a Target for Drug Development in Down Syndrome.

Authors:  Arnaud Duchon; Yann Herault
Journal:  Front Behav Neurosci       Date:  2016-06-03       Impact factor: 3.558

4.  Correction of cognitive deficits in mouse models of Down syndrome by a pharmacological inhibitor of DYRK1A.

Authors:  Thu Lan Nguyen; Arnaud Duchon; Antigoni Manousopoulou; Nadège Loaëc; Benoît Villiers; Guillaume Pani; Meltem Karatas; Anna E Mechling; Laura-Adela Harsan; Emmanuelle Limanton; Jean-Pierre Bazureau; François Carreaux; Spiros D Garbis; Laurent Meijer; Yann Herault
Journal:  Dis Model Mech       Date:  2018-09-27       Impact factor: 5.758

Review 5.  Care and feeding of the endocannabinoid system: a systematic review of potential clinical interventions that upregulate the endocannabinoid system.

Authors:  John M McPartland; Geoffrey W Guy; Vincenzo Di Marzo
Journal:  PLoS One       Date:  2014-03-12       Impact factor: 3.240

Review 6.  Small Molecules from Nature Targeting G-Protein Coupled Cannabinoid Receptors: Potential Leads for Drug Discovery and Development.

Authors:  Charu Sharma; Bassem Sadek; Sameer N Goyal; Satyesh Sinha; Mohammad Amjad Kamal; Shreesh Ojha
Journal:  Evid Based Complement Alternat Med       Date:  2015-11-17       Impact factor: 2.629

7.  A Polyphenols-Rich Extract from Moricandia sinaica Boiss. Exhibits Analgesic, Anti-Inflammatory and Antipyretic Activities In Vivo.

Authors:  Sahar El-Mekkawy; Abdelaaty A Shahat; Ali S Alqahtani; Mansour S Alsaid; Mohamed A O Abdelfattah; Riaz Ullah; Mahmoud Emam; Abdelaziz Yasri; Mansour Sobeh
Journal:  Molecules       Date:  2020-10-30       Impact factor: 4.411

8.  Radionuclides Transfer from Soil to Tea Leaves and Estimation of Committed Effective Dose to the Bangladesh Populace.

Authors:  Nurul Absar; Jainal Abedin; Md Mashiur Rahman; Moazzem Hossain Miah; Naziba Siddique; Masud Kamal; Mantazul Islam Chowdhury; Abdelmoneim Adam Mohamed Sulieman; Mohammad Rashed Iqbal Faruque; Mayeen Uddin Khandaker; David Andrew Bradley; Abdullah Alsubaie
Journal:  Life (Basel)       Date:  2021-03-27
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.